KnowledgeLink Newsletter

July 2008

Decision-makers in R&D, corporate finance, business strategy, marketing planning and corporate communications have a new tool to call on. The CMR International 2008 Pharmaceutical R&D Factbook provides a reliable, quotable source of key reference metrics and an insight into current industry trends.

CMR International, a Thomson Reuters business, is the world leader in global pharmaceutical R&D performance measurement. For almost 15 years, CMR International has worked with the leading global pharmaceutical companies to assess R&D productivity and provide insights into industry trends that are used to strengthen the planning and effectiveness of R&D.

Since 2003, CMR International has published the Pharmaceutical R&D Factbook, an annual report designed to equip those working in, or with an interest in, the Pharmaceutical R&D Sector with a reliable quotable source of key reference metrics and an insight into current industry trends. These metrics are exclusively from primary sources, including all major pharmaceutical companies who between them account for approximately 80 per cent of the industry's global spend on research and development. They include charts on:

• global and regional R&D expenditure
• drug R&D success rates and cycle times
• trends in pipeline composition, including in-licensing
• clinical studies timescale and enrolment trends
• therapy area performance

Each chart is accompanied by a clear explanation of the methodology used and the definitions applied, so it can be quoted with total confidence — and is, throughout the industry.

This year's report is bigger than ever before, incorporating information from other leading Thomson Reuters sources that provide insight into areas such as generics and patents. Trends emerging from this year's analysis include:

• Marked increases across companies of all sizes in the mean number of active substances that they are developing — an early indicator that productivity should improve
• Large increases in the number of development projects that are arising from Collaborative ventures — suggests that the model is changing
• A clear shift in patient enrolment to emerging markets

CMR International 2008 Pharmaceutical R&D Factbook: overview, pricing and ordering information